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Supplementary Figure S1. Node degree distributions for the CAC network. (a) In-degree 
distribution P(kin) and out-degree distribution P(kout) for the CAC network. It is worth noting that, 
as we removed dangling nodes (nodes with zero out-degree and only one in-degree) to simplify 
the network topology, the number of nodes with in-degree of one is decreased and deviate from 
the power-law distribution. However, this simplification should not impact the dynamic properties 
of the CAC network, with which we are more concerned. The insets suggest the degree 
distributions follow power-law distributions if the nodes of degree one are omitted.  
 
 
Supplementary Figure S2. Robustness test of the CAC network. (a) Perturbation of the initial 
node states. One hundred initial states were randomly generated and the states of one, two or three 
randomly chosen nodes were flipped. The averaged states of all the nodes were recorded, after 
5,000 rounds of iterations using the general asynchronous updating methods from perturbed and 
unperturbed initial states. The root-mean-square error (RMSE) between the simulation results 
from unperturbed initial states and perturbed ones were calculated. According to the distribution of 
RMSE values, the majority of the RMSE values are small (between 0.00 and 0.02), indicating the 
network model is robust to small amounts of noise in the initial network states. (b) Perturbation of 
deleting interaction (edge). One hundred initial states were randomly generated and one, two or 
three randomly chosen edges were deleted. In a similar manner, the RMSE values between the 
simulations results of the unperturbed networks and perturbed ones were calculated. The results 
also indicate the network model is robust to small changes in the topology structure.  
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Supplementary Figure S3. The fluctuation of the activation frequencies of the immune cell 
nodes when the initial state of DC was set in ON state (transient activation).  
 
 
Supplementary Figure S4. The activation frequencies of Proliferation, Apoptosis, STAT3, 
NFKB and BCATENIN under the pro-tumor inflammatory microenvironment (DC in ON 
state) while APC was kept in OFF state, mimicking the APC inactive mutation observed in 
colorectal cancers.  
 
 
Supplementary Figure S5. Node perturbations on the CAC network model in P53 inactive 
state.  
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Supplementary Figure S6. (a) Immunoblots of lysates of HT29 cells after treatment with 
inflammatory cytokine IL6 and TNF- for 30min.  (b) Immunoblots of lysates from cells in 
which AKT1,2,3 were depleted by siRNA. (c-f) Cell viabilities detected at 48 h after 
combinatorial treatments of Lapatinib and C2-ceramide (c), Gefitinib and C2-ceramide (d), 
GDC0941 and FTY720 (e) and FTY720 and MK2206 (f). (g) Ceramide levels in HT29 cells 
determined by HPLC-ESI-MS/MS assay after FTY720 treatment for 6 h. TC means total 
ceramide (C2-, C14-, C16-, C18-, C20-, and C22-ceramide). The intracellular concentrations 
of C2-, C18- and C20- ceramides were very low compared with that of C14-, C16- and C22- 
ceramides. 
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Supplementary Table S1. The full names of components in the CAC network 
corresponding to the abbreviated node labels used. 
Node name Gene symbol Full name 
AKT AKT1/AKT2 v-akt murine thymoma viral oncogene homolog 1 / 
v-akt murine thymoma viral oncogene homolog 2 
APC APC  adenomatous polyposis coli 
ASK1 MAP3K5 apoptosis signal-regulating kinase 1 (also known as mitogen-activated 
protein kinase kinase kinase 5) 
ATM ATM ataxia telangiectasia mutated 
BAX BAX BCL2-associated X protein 
BCATENIN CTNNB1 beta-catenin 
BCL2 BCL2 B-cell CLL/lymphoma 2 
CASP3 CASP3 caspase 3, apoptosis-related cysteine peptidase 
CASP8 CASP8 caspase 8, apoptosis-related cysteine peptidase 
CASP9 CASP9 caspase 9, apoptosis-related cysteine peptidase 
CCL2 CCL2 chemokine (C-C motif) ligand 2 
CERAMIDE N/A ceramide 
CFLIP CFLAR CASP8 and FADD-like apoptosis regulator 
COX2 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase 
and cyclooxygenase) 
CTL N/A CD8+ cytotoxtic lymphocyte 
CYCLIND1 CCND1 cyclin D1 
CYTC CYCS cytochrome c, somatic 
DC N/A dendritic cells 
EP2 PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa 
ERK MAPK1/MAPK3 mitogen-activated protein kinase 1/ mitogen-activated protein kinase 
3 (also known as ERK1 and ERK2) 
FADD FADD Fas (TNFRSF6)-associated via death domain 
FAS FAS Fas (TNF receptor superfamily, member 6) 
FOS FOS FBJ murine osteosarcoma viral oncogene homolog 
GP130 IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) 
GSK3B GSK3B glycogen synthase kinase 3 beta 
IAP XIAP/BIRC3/BIRC2 X-linked inhibitor of apoptosis / baculoviral IAP repeat containing 3 / 
baculoviral IAP repeat containing 2 
IFNG IFNG interferon, gamma 
IKB NFKBIA/NFKBIB nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha/beta 
IKK CHUK/IKBKB conserved helix–loop–helix ubiquitous kinase / inhibitor of kappa 
light polypeptide gene enhancer in B-cells, kinase beta (also known as 
IKK-alpha and IKK-beta) 
IL10 IL10 interleukin 10 
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Node name Gene symbol Full name 
IL12 IL12A interleukin 12A 
IL4 IL4 interleukin 4 
IL6 IL6 interleukin 6 (interferon, beta 2) 
JAK JAK2 Janus kinase 2 
JNK MAPK8 mitogen-activated protein kinase 8 
JUN JUN jun proto-oncogene 
MAC N/A macrophages 
MDM2 MDM2 Mdm2, p53 E3 ubiquitin protein ligase homolog (mouse) 
MEK MAP2K1/MAP2K2 mitogen-activated protein kinase kinase 1 / mitogen-activated 
protein kinase kinase 2 (also known as MEK1 and MEK2) 
MEKK1   MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin 
protein ligase 
MOMP N/A mitochondrial outer membrane permiabilization 
NFKB NFKB1/NFKB2/RELA nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 1 (p105) / nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 (p49/p100) / v-rel reticuloendotheliosis 
viral oncogene homolog A, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3, p65 (avian) 
P21 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
P53 TP53 tumor protein p53 
PGE2 N/A prostaglandin E2 
PI3K PIK3CA/PIK3CB phosphoinositide-3-kinase, catalytic, alpha polypeptide / 
phosphoinositide-3-kinase, catalytic, beta polypeptide 
PP2A PPP2CA/PPP2CB protein phosphatase 2, catalytic subunit, alpha isoform / protein 
phosphatase 2, catalytic subunit, beta isozyme 
PTEN PTEN phosphatase and tensin homolog 
RAF RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 
RAS KRAS/HRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog / 
v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
ROS N/A reactive oxygen species 
S1P N/A Sphingosine-1-phosphate 
SMAC DIABLO diablo, IAP-binding mitochondrial protein 
SMAD SMAD2/SMAD3/SMAD4 SMAD family member 2/3/4 
SMAD7 SMAD7 SMAD family member 7 
SMASE SMPD1/SMPD2/SMPD4 sphingomyelin phosphodiesterase 1, acid lysosomal / 
sphingomyelin phosphodiesterase 2, neutral membrane (neutral 
sphingomyelinase) / sphingomyelin phosphodiesterase 4, 
neutral membrane (neutral sphingomyelinase-3) 
SOCS   SOCS1 suppressor of cytokine signaling 1 
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Node name Gene symbol Full name 
SOD SOD1/SOD2 superoxide dismutase 1, soluble / superoxide dismutase 2, mitochondrial 
(also known as Cu/ZN-SOD and Mn-SOD) 
SPHK1 SPHK1 sphingosine kinase 1 
STAT3 STAT3 signal transducer and activator of transcription 3 (acute-phase response 
factor) 
TBID BID BH3 interacting domain death agonist 
TGFB TGFB1/TGFB2 transforming growth factor, beta 1 / transforming growth factor, beta 2 
TGFR TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 
TH1 N/A type 1 T helper cells 
TH2 N/A type 2 T helper cells 
TNFA TNF tumor necrosis factor 
TNFR TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 
TREG N/A regulatory T cells 
 
 
 
 
 
Supplementary Table S2. Topology properties of the CAC network and random 
networks with the same node and edge number. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Network property CAC network Random networks 
Nodes 70 70 
Edges 153 153 
Average node connectivity 3.15 3.20±0.1 
Clustering coefficient 0.10 0.06±0.02 
Shortest path length 3.37 2.98±0.05 
The average values and standard deviations of the network properties were 
calculated from a ensemble of 1,000 random networks. 
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Supplementary Table S3. Boolean logical rules that govern the state of the nodes in CAC 
network.  
ATM* = ROS 
ASK1* = ROS and not P21 
AKT* = PI3K and not (PP2A or CASP3) 
BAX* = ((TBID or P53) and PP2A) and not AKT 
BCATENIN* = not (GSK3B and APC) 
BCL2* = (STAT3 or NFKB) and not (P53 or PP2A) 
CASP3* = (CASP8 or CASP9) and not IAP 
CASP8* = FADD and not (CFLIP or P21) 
CASP9* = CYTC and not (IAP or P21) 
CERAMIDE* = SMASE and not SPHK1 
CFLIP* = NFKB 
COX2* = S1P and TNFR 
CYCLIND1* = (BCATENIN or STAT3 or JUN) and not GSK3B 
CYTC* = MOMP 
EP2* = PGE2 
ERK* = MEK 
FAS* = CTL 
FADD* = TNFR or FAS 
FOS* = ERK 
GP130* = IL6 
GSK3B* = not (EP2 or AKT) 
IAP* = (NFKB or STAT3) and not SMAC 
IKB* = not IKK 
IKK* = (AKT or (S1P and TNFR)) 
JAK* = GP130 and not SOCS 
JNK* = ASK1 or MEKK1 
JUN* = ((BCATENIN or ERK) and JNK) and not GSK3B 
MDM2* = (P53 and AKT) and not (GSK3B or ATM) 
MEK* = RAF or ROS 
MEKK1* = CERAMIDE or TGFR or TNFR 
MOMP* = (BAX or TBID or CERAMIDE) and not BCL2 
NFKB* = not IKB 
P21* = (P53 or SMAD) and not (GSK3B or CASP3) 
P53* = (PTEN or JNK or ATM) and not MDM2 
PGE2* = COX2 
PI3K* = (EP2 or RAS) and not PTEN 
PP2A* = CERAMIDE and not AKT 
PTEN* = P53 and not (NFKB or JUN) 
RAF* = CERAMIDE or RAS 
RAS* = EP2 or GP130 
ROS* = TNFR and not SOD 
SOD* = NFKB or STAT3 
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S1P* = SPHK1 
SMAC* = MOMP 
SMAD* = TGFR and not JUN 
SMAD7* = SMAD or NFKB 
SMASE* = P53 or FADD 
SPHK1* = ERK or TNFR 
STAT3* = JAK 
SOCS* = STAT3 
TBID* = CASP8 and not BCL2 
TGFR* = TGFB and not SMAD7 
TNFR* = TNFA 
TREG* = (IL10 or DC) and not IL6 
TNFA* = MAC 
TH2* = IL4 and not (IFNG or TGFB) 
TH1* = (IL12 or IFNG) and not (IL10 or TGFB or IL4) 
TGFB* = TREG 
MAC* = (IFNG or CCL2) and not IL10 
IL6* = MAC or DC or NFKB 
IL4* = DC or TH2 
IL12* = DC or MAC 
IL10* = TREG or TH2 
IFNG* = TH1 or CTL 
CTL* = IFNG and not TGFB 
DC* =  (CCL2 or TNFA) and not IL10 
CCL2* = NFKB 
Proliferation* = (FOS and CYCLIND1) and not (P21 or CASP3) 
Apoptosis* = CASP3 
“Node*” denotes the next state of the same node on the left-hand side of the equation, which is 
determined by the states of its regulators according to the function on the right-hand side of the 
equation. 
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Supplementary Table S4. Attractors of the CAC network under the non-inflammatory 
microenvironment and normal inflammatory response.  
Conditions 
Attractors 
ID Type Length 2Basin size 
2Exclusive 
basin size 
Phenotype 
Non-inflammatory 
microenvironment 
1 Fixed point 1 75.0% 6.25% Resting 
2 Complex attractor 192 93.8% 25.0% 
1Limited 
apoptosis 
Normal 
inflammatory 
response 
1 Fixed point 1 13.6% 0% Resting 
2 Fixed point 1 34.4% 1.12% Apoptosis 
3 Complex attractor 96 16.7% 11.1% Proliferation 
4 Complex attractor 6 56.0% 10.5% Proliferation 
5 Complex attractor 1345 19.5% 2.94% Apoptosis 
1Under the non-inflammatory microenvironment, the Apoptosis node oscillated between ON 
and OFF in the complex attractor, and therefore this attractor represented a limited apoptosis 
phenotype.  
2The attractors can have shared basins since the general asynchronous updating method was 
used. Therefore, both the total basin size and the exclusive basin size were calculated for each 
attractor. 
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Supplementary Table S5. Boolean logical rules governing the nodes’ states in the 
21-node sub-network presented in Figure 3b.  
AKT* = not PTEN 
BCATENIN* = not (P53 and GSK3B) 
CTL* = IFNG and not IL10 
CYCLIND1* = (BCATENIN or STAT3 or JUN) and not GSK3B 
GSK3B* = not (TNFR or AKT) 
IFNG* = CTL 
IKK* = AKT or TNFR 
IL10* = not IFNG 
JAK* = not SOCS 
JNK* = TNFR 
JUN* = JNK and not GSK3B 
MAC* = (IFNG or NFKB) and not IL10 
MDM2* = (P53 and AKT) and not GSK3B 
NFKB* = IKK 
P21* = P53 and not GSK3B 
P53* = (PTEN or JNK) and not MDM2 
PTEN* = P53 and not (NFKB or JUN) 
SOCS* = STAT3 
STAT3* = JAK 
TNFR* = MAC 
Proliferation* = CYCLIND1 and not P21 
“Node*” denotes the next state of the same node on the left-hand side of the equation, which is 
determined by the states of its regulators according to the function on the right-hand side of the 
equation. 
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Supplementary Table S6. Attractors of the reduced CAC network model shown in figure 
3b, when synchronous updating method was used. 
ID Cycle length Basin size Phenotype 
1 2 0.19% 
Resting 
2 6 0.57% 
3 6 0.02% 
4 6 0.71% 
5 2 0.23% 
6 2 0.01% 
7 6 0.02% 
8 6 0.70% 
9 6 0.71% 
10 2 0.24% 
11 6 0.57% 
12 6 0.02% 
13 2 0.23% 
14 6 0.70% 
15 2 0.009% 
16 2 0.19% 
17 2 0.007% 
18 2 0.24% 
  Sum: 5.4% 
19 4 3.1% 
Limited Proliferation 
20 12 17% 
21 4 5.8% 
22 12 9.3% 
23 12 9.3% 
24 4 3.1% 
25 4 5.8% 
26 12 17% 
  Sum: 71.5% 
27 2 5.8% 
Proliferation 28 6 17.3% 
  Sum: 23.1% 
All the attractors are limited cycles when synchronous updating method was used. 
 
 
 
 
13 
 
 
Supplementary Table S7. Comparison of the simulation results using different updating 
methods. 
 
 
 
 
 
 
Condition 
Updating 
method 
Nodes’ activation frequency 
Proliferation Apoptosis STAT3 NFKB BCATENIN
Non-inflammatory 
microenvironment 
GA 0 0.36 0 0 0 
ROA 0 0.33 0 0 0 
Sync 0 0.28 0 0 0 
Normal 
inflammation 
response 
GA 0.40 0.30 0.25 0.50 0.53 
ROA 0.43 0.30 0.27 0.55 0.54 
Sync 0.74 0.18 0.43 0.76 0.75 
Pro-tumor 
microenvironment 
GA 0.63 0 0.51 0.69 0.69 
ROA 0.67 0 0.50 0.71 0.71 
Sync 0.88 0 0.50 0.92 0.91 
Pro-tumor 
microenvironment 
and P53 inactivation
GA 1 0 0.46 1 1 
ROA 1 0 0.49 1 1 
Sync 1 0 0.50 1 1 
GA: General asynchronous; ROA: Random order asynchronous; Sync: Synchronous 
When different updating methods were used, the changes of the major simulation results showed 
similar trends under various conditions: under the non-inflammatory microenvironment, the 
Proliferation node stabilised in the OFF state while the Apoptosis node had a small chance to be 
activated (around 30%); The normal inflammation response (transient activation of the DC node) 
increased the activation frequency of Proliferation while the activation of Apoptosis was not 
significantly inhibited; The constant activation of the DC node, which formed the pro-tumor 
microenvironment, further increased the activation of Proliferation and inhibited Apoptosis, but 
the activation frequency of Proliferation did not reach 100%. Keeping P53 node at OFF state 
under pro-tumor microenvironment led all the simulation trajectories fall into the attractor that 
represents proliferation state. The impact of different microenvironments on the activation 
probabilities of STAT3, NFKB and BCATENIN, which represents the previously identified three 
major players in CAC, also followed a similar trend. 
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Supplementary Table S8. Comparison between the single node perturbation effects with 
experimental studies. 
Node Perturbation Effect Reference Experiment model 
P53 - Pro-proliferative 1, 2 Colon tumor tissues 
MDM2 + Pro-proliferative 3 Patient samples 
PI3K + Pro-proliferative 4, 5 Several colon cancer cell lines 
AKT + Pro-proliferative 6 Colo205 and tumor tissues 
PTEN - Pro-proliferative 7 Colon tumor tissues 
NFKB + Pro-proliferative 8 Colon tumor tissue 
IKK + Pro-proliferative 9 Mouse model 
IKB - Pro-proliferative 8 Colon tumor tissue 
JUN + Pro-proliferative 10 HCT116 
CYCLIND1 + Pro-proliferative 11 Colon tumor tissues 
GSK3B - Pro-proliferative 12 SW480 and AGS 
PGE2 + Pro-proliferative 13, 14 Cell lines and mouse model 
EP2 + Pro-proliferative 15 Mouse model 
COX2 + Pro-proliferative 13 Colon cancer cell lines 
AKT - Anti-proliferative 16 Clinical trials 
PI3K - Anti-proliferative 17, 18 Cell lines and xenograft model 
PTEN + Anti-proliferative 19 Colon cancer cell lines 
ATM + Anti-proliferative - - 
P53 + Anti-proliferative 20 HCT116 
P21 + Anti-proliferative 21 HT29 
SMAD + Anti-proliferative - - 
ROS + Anti-proliferative - - 
GSK3B + Anti-proliferative - - 
FOS - Anti-proliferative - - 
CYCLIND1 - Anti-proliferative 22 SW480 
GP130 - Pro-apoptosis 23 SW480 
RAS - Pro-apoptosis 24 Mouse model 
RAF - Pro-apoptosis 25, 26 Colon cancer cell lines 
PP2A + Pro-apoptosis - - 
MEK - Pro-apoptosis 26, 27 Cell lines and mouse model 
ERK - Pro-apoptosis 26 Colon cancer cell lines 
IL6 - Pro-apoptosis 28 Mouse model 
SPHK1 - Pro-apoptosis 29 Mouse model 
CERAMIDE + Pro-apoptosis - - 
MOMP + Pro-apoptosis 30 HCT116 
CASP3 + Pro-apoptosis 31, 32 Colo205 and SNU-C4 
The shaded lines represent the in silico perturbation effects that have not been reported by 
experimental studies. These experimental results were not used in the model construction, and 
therefore they can regarded as the external sources to validate the CAC network model. 
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Supplementary Methods 
Biological Description of the CAC network 
The sustained inflammatory responses in inflammatory bowel disease (IBD) involve an 
overactivated innate and adaptive immune response1. The inflammatory responses can be initiated 
by antigen-presenting cells such as dendritic cells (DC)2. IL-12 (IL12) secreted by activated DCs 
initiate Th1 immune response, which promotes cell-mediated immunity. Th1 cells (TH1) further 
mediate the activation of CD8+ cytotoxic T cells (CTL), which play crucial roles in immune 
surveillance3. In addition, Th1 cells also mediate the activation of macrophages (MAC), which are 
considered as the major source of pro-inflammatory cytokines such as TNF- (TNFA) and IL-6 
(IL6)2, 4. DCs also produce the pro-inflammatory cytokine, IL-6, during IBD development5. IL-4 
(IL4) secreted by DCs initiates humoral immunity by activating Th2 cells (TH2). Th1 responses 
and Th2 responses counteract each other: Th1 responses are inhibited by Th2 cytokines such as 
IL-4 and IL-10, while Th2 responses are inhibited by Th1 cytokines such as IFN- (IFNG)6. DCs 
also drive the differentiation of regulatory T cells (TREG), resulting in the production of immune 
suppressive cytokines, TGF- (TGFB) and IL-10 (IL10) 7, 8, which have been shown to alleviate 
IBD and lower tumor incidence in CAC cases9.  
The immune microenvironment affects the growth and survival of epithelial cells through 
cytokines or direct interactions between immune cells and epithelial cells. Meanwhile, cytokines 
and chemokines produced by epithelial cells, such as IL-6 and CCL2, also take part in shaping the 
immune microenvironment by regulating immune cells2, 5, 10. Pro-inflammatory cytokines, such as 
TNF- and IL-6 produced by immune cells, support the proliferation and survival of premalignant 
intestine epithelial cells (IECs) as well as newly emerged neoplastic cells during chronic 
inflammation9. TNF- binds to the TNF- receptor (TNFR) expressed on the cell membrane of 
IECs and initiates NF-B signaling. The NF-B transcription factor up-regulates multiple genes 
that correlate with cell survival such as Bcl-2 (BCL2), c-Flip (CFLIP), c-IAPs (IAP) and XIAP11. 
However, upon activation, TNFR also recruits FADD and initiates caspase-8 (CASP8) dependent 
apoptotic cell death, which can be blocked by c-Flip12. In addition, the activation of TNFR couples 
with several cellular processes such as production of ROS, up-regulation of COX2 and activating 
the JNK pathway12, 13, 14. Except for TNF-, IL-6 signaling has also been proven to play important 
roles in IBDs and CAC development15. Activation of gp130 by IL-6 leads to the phosphorylation 
and nuclear translocation of STAT3 transcription factor15. Similar to NF-B, STAT3 enhances cell 
survival by up-regulating Bcl-2 and c-IAPs11. STAT3 can also promote cell proliferation by 
driving the expression of Cyclin D1 (CYCLIND1)16. Except for signaling through STAT3, gp130 
also activates ERK MAPK signaling cascade to promote cell proliferation17.  
In addition to the promoting effect on cell survival and proliferation, the immune 
microenvironment also exerts anti-proliferation and pro-apoptosis effect on IECs. TGF- secreted 
by immune cells not only suppresses the inflammatory response, but also suppresses cell 
proliferation through TGF-/SMADs signaling18. Cytotoxic T lymphocytes (CTL) activated by 
Th1 cells express Fas ligand (FASL) and initiate Fas mediated apoptosis of epithelial cells19. This 
process also involves the activation of caspase-8 and can be blocked by c-Flip20.  
Except for those four pathways (TNF-/NF-B, IL-6/STAT3, TGF-/SMADs, and FasL/Fas) that 
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mediate the crosstalk between immune microenvironment and epithelial cells, recent studies also 
emphasize sphingolipid signaling in inflammation and cancer development5. Binding of TNF- to 
TNFR activates SPHK1, which is a key regulator of sphingolipid metabolism. SPHK1 produces 
sphingosine 1-phosphate (S1P), another bioactive sphingolipid metabolite that has been shown to 
correlate with cell proliferation and survival. S1P is also a cofactor of TRAF2 and plays an 
essential role in initiating NF-B signaling21. SPHK1 activation also decreases the cellular level of 
another sphingolipid metabolite, ceramide, which plays an opposite role to S1P22. Moreover, 
TNF- signaling also leads to the generation of ceramide by activating sphingomyelinase23, 24. 
Ceramide inhibits cell proliferation and induces apoptosis through directly binding and activating 
PP2A and MEKK1. Ceramide has also been shown to directly trigger mitochondrial outer 
membrane permeabilization (MOMP), leading to the release of pro-apoptotic proteins such as 
cytochrome C (CYTC) and Smac (SMAC)25. These proteins are able to initiate mitochondrial 
apoptosis pathways, which involves the sequential activation of caspase-9 (CASP9) and caspase-3 
(CASP3)25. Further , PGE2, another lipid signaling molecule, has been shown to play important 
roles in CAC26. PGE2 binds to the EP2 receptor on epithelial cells and activates 
RAS/RAF/MEK/ERK signaling as well as PI3K/AKT signaling, two pathways that tightly 
correlate with cell growth and survival27, 28. In addition, activated EP2 leads to the 
phosphorylation and inhibition of glycogen synthase kinase-3 (GSK3B) and therefore promotes 
-catenin signaling29. Increased activity of -catenin has been observed in both CAC and sporadic 
colon cancers9. 
Detailed explanation of the Boolean rules of the CAC network. 
TNFA* = MAC  
TNFR* = TNFA 
FADD* = TNFR or FAS 
IKK* = AKT or (S1P and TNFR) 
IKB* = not IKK 
NFKB* = not IKB 
FAS* = CTL 
COX2* = S1P and TNFR 
PGE2* = COX2 
EP2* = PGE2 
S1P* = SPHK1 
SPHK1* = ERK or TNFR 
 
In IBDs such as Crohn’s disease and ulcerative colitis, activated macrophages are the major 
source of TNF-4. TNF- binds to TNF- receptors and activates their downstream target 
tumor necrosis factor receptor 1-associated death domain (TRADD)12. On one hand, the 
interaction between TRADD and Fas-Associated protein with Death Domain (FADD) 
stimulates the activation of caspase-8 (represented as CASP8), which is the initiator caspase 
of the death receptor pathway of apoptosis12. Binding of Fas ligand expressed on CTL to Fas 
on epithelial cells or tumor cells can also recruit and activate FADD19. On the other hand, 
TRADD recruits TNF receptor-associated factor 2 (TRAF2), which can in turn recruit and 
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activate IB kinase (IKK) and initiate NF-B signaling. In unstimulated cells, NF-B dimers 
(represented as NFKB) are sequestered in cytoplasm by a family of inhibitors called IB 
(represented by “IKB”). The activated IKK leads to the phosphorylation and subsequent 
degradation of IB, which enables the nuclear translocation and activation of NF-B 
transcription factor12. TNFR, TRADD and TRAF2 are collapsed into “TNFR” in the Boolean 
rules. A recent study identified S1P as a missing cofactor of TRAF2 and showed S1P played a 
key role in canonical NF-B activation21. Therefore, an “AND” is used between TNFR and 
S1P to indicate their synergistic positive effect on IKK in the Boolean rules. In addition, 
NF-B can be activated through PI3K/AKT/IKK pathway independent of TNF- signaling30, 
31. Regulation of cyclooxygenase-2 (COX2) expression and PGE2 (represented by “PGE2”) 
production by the SPHK1/S1P pathway plays an important role in colon carcinogenesis32. As 
the up-regulation of COX2 by S1P may be TNF- dependent, an “AND” is used to link 
“S1P” and “TNFR”. The actions of PGE2 are mediated by signaling through four G 
protein-coupled receptors EP1, EP2, EP3 and EP4 (represented by “EP2”)33. Although two 
isoforms of sphingosine kinase (SPHK1 and SPHK2) are responsible for the generation of 
S1P, SPHK1 is considered as the major source of S1P during colitis and colon carcinogenesis5, 
34. SPHK1 can be recruited and activated by TNF receptor21, 35 and it can also be 
phosphorylated and activated by Erk1/2 (ERK)36.  
 
IL6* = MAC or DC or NFKB 
GP130* = IL6 
JAK* = GP130 and not SOCS 
STAT3* = JAK 
SOCS* = STAT3 
RAS* = EP2 or GP130 
RAF* = CERAMIDE or RAS 
MEK* = RAF or ROS 
ERK* = MEK 
FOS* = ERK 
PI3K* = (EP2 or RAS) and not PTEN 
PTEN* = P53 and not (NFKB or JUN) 
AKT* = PI3K and not (PP2A or CASP3) 
PP2A* = CERAMIDE and not AKT 
CERAMIDE* = SMASE and not SPHK1 
SMASE* = P53 or FADD 
 
Macrophage and dendritic cells act as the major source of IL-6 (represented by “IL6”) during 
the development of CAC2, 5. Meantime, IECs also produce IL-6 through the activation of 
NF-B2, 5. The interaction between IL-6 and its receptor triggers the gp130 and IL-6R proteins 
to form a complex (represented by “GP130”), resulting in the activation of the associated 
Janus kinase 2 (JAK2, represented as “JAK”). This leads to the subsequent phosphorylation 
and dimerization of Signal transducer and activator of transcription 3 (STAT3). Then the 
dimerized STAT3 protein translocates into cell nucleus and activates the transcription of its 
targets genes. Suppressor of cytokine signaling proteins (SOCS) are well-known STAT3 
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target genes, which are also involved in inhibiting JAK-STAT signaling, thus forming a 
negative feed-back loop in the CAC network. In addition, activated gp130 or PGE2 also leads 
to the activation of ERK MAPK signaling (RAS/RAF/MEK/ERK)17, 37, resulting in the 
activation of proto-oncogene c-Fos (represented by “FOS”)38. Raf kinase (RAF) within the 
ERK/MAPK pathway has been shown to be directly phosphorylated and activated by 
ceramide-activated protein (CAP) kinase (“CERAMIDE” and “CAPK” are collapsed in to 
“CERAMIDE”)39. Reactive oxygen species (ROS) are also well known to induce the 
activation of the ERK/MAPK pathway. This action occurs on an upstream regulator of 
ERK1/2, as the inhibitors (U0126 and PD98059) of MEK1 and 2 both blocked the oxidative 
stress-induced ERK1/2 activation40.  
PGE2 activates the of PI3K/AKT pathway through EP2 or EP4 receptors27. PI3Ks can also be 
directly stimulated by GTP-bound Ras41 and activation of the PI3K/AKT pathway via K-ras 
mutations is considered one of the most common mechanisms involved in colorectal 
carcinogenesis42. PTEN protein acts as a phosphatase to dephosphorylate phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) and thus suppresses PI3K activation43. PTEN is a tumor 
suppressor gene that is positively regulated by p5344and negatively regulated by NF-B45. 
Activation of c-Jun, a component of the AP-1 family of transcription factor, also leads to the 
down-regulation of PTEN gene46. Activated Akt (AKT) can be inhibited through 
dephosphorylation by Protein phosphatase 2 (PP2A)47 or direct cleavage by caspase-348. 
PP2A can be negatively regulated by mammalian target of rapamycin (mTOR)49, 50, which is 
activated by the PI3K/AKT pathway (mTOR and its direct upstream regulator AKT are 
collapsed into “AKT”). While ceramides stimulate PP2A directly or through inhibiting an 
endogenous PP2A inhibitor, I2PP2A51, 52. Ceramides are generated by sphingomyelinases 
(represented by “SMASE”), which directly hydrolyse sphingomyelins into ceramides. Neutral 
sphingomyelinases can be activated by P53 while acid sphingomyelinases are activated by 
TNF receptors through FADD23, 24. As ceramides are the precursors of S1P, SPHK1 also 
tightly regulates the cellular level of ceramides22. 
 
CASP8* = FADD and not (CFLIP or P21) 
CFLIP* = NFKB 
TBID* = CASP8 and not BCL2 
BAX* = ((TBID or P53) and PP2A) and not AKT 
BCL2* = (STAT3 or NFKB) and not (P53 or PP2A) 
CYTC* = MOMP 
SMAC* = MOMP 
MOMP* = (BAX or TBID or CERAMIDE) and not BCL2 
CASP3* = (CASP8 or CASP9) and not IAP 
CASP9* = CYTC and not (IAP or P21) 
IAP* = (NFKB or STAT3) and not SMAC 
Apoptosis* = CASP3 
 
The extrinsic apoptosis pathway is initiated by the activation of caspase-8 (represented by 
“CASP8”). However, the activation of caspase-8 can be inhibited by p21/WAF1 (represented 
by “P21”)53 or c-FLIP (represented by “CFLIP”)20, a downstream target of NF-B(NFKB)54. 
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Activated caspase-8 cleavages BID and generates truncated BID (tBID, represented by 
“TBID”), which in turn mediates the mitochondria damage such as mitochondrial outer 
membrane permeabilization (MOMP)55. MOMP can also be induced by the intrinsic pathway 
which involves the dynamic balance of Bcl-2 family of proteins. The pro-apoptotic members 
of this family, such as Bax and Bak (represented by “BAX”), can trigger MOMP while the 
anti-apoptotic members, such as Bcl-2 and Bcl-xL (represented by “BCL2”), prevent 
MOMP56. The pro-apoptotic sphingolipid ceramide (CERAMIDE), can also trigger MOMP 
through forming ceramide channels or other mechanisms57. P53 activates Bax through 
up-regulating bax gene expression or by directly associating with Bax protein58, 59. Bax and 
Bak can also be activated by tBID60. The phosphorylation of Bax by Akt (AKT) inhibits Bax 
effects on the mitochondria by maintaining the protein in the cytoplasm, heterodimerized with 
anti-apoptotic Bcl-2 family members61. Since the dephosphorylation of Bax by PP2A is 
required for its effect on mitochondria, an “AND” is used between PP2A and “P53 or 
TBID”62. The occurrence of MOMP leads to the release of pro-apoptotic proteins such as 
Smac/DIABLO (SMAC) and cytochrome c (represented by “CYTC”)63. Cytosolic 
cytochrome c binds to Apaf-1 and triggers the formation of the apoptosome, which mediates 
the activation of caspase-9 (represented by “CASP9”), which is inhibited by P2153. Activated 
caspase-9 cleaves and activates downstream executioner caspases such as caspase-3 
(represented by “CASP3”)64, which can also be cleaved and activated by caspase-864. The 
activation of executioner caspases such as caspase-3 initiates the apoptosis event and is 
generally considered as “a point of no return”65. Members of the Inhibitors of Apoptosis 
(IAPs) family, such as XIAP and cIAPs (represented by “IAP”), inhibit the activity of 
caspase-3 and caspase-963. IAPs are positively regulated by both STAT3 and NF-B11 while 
they are inhibited by Smac/DIABLO through direct binding63. STAT3 and NF-B also 
enhance cell survival through up-regulating anti-apoptotic Bcl-2 family members such as 
Bcl-2 and Bcl-xL (represented as “BCL2”). On the other hand, Bcl-2 family members have 
been shown to be down-regulated by P5366 and can be inhibited through dephosphorylation 
by PP2A67. 
 
ROS* = TNFR and not SOD 
SOD* = NFKB or STAT3 
ASK1* = ROS and not P21 
JNK* = ASK1 or MEKK1 
MEKK1* = CERAMIDE or TGFR or TNFR 
JUN* = ((BCATENIN or ERK) and JNK) and not GSK3B 
GSK3B* = not (EP2 or AKT) 
BCATENIN* = not (GSK3B and APC) 
CYCLIND1* = (BCATENIN or STAT3 or JUN) and not GSK3B 
Proliferation* = (FOS and CYCLIND1) and not (P21 or CASP3) 
 
Reactive oxygen species (ROS) can be generated by TNF through activated TNF receptors13. 
NF-B and STAT3 signaling up-regulates superoxide dismutases (represented by “SOD”), 
which  eliminates ROS rapidly11. Accumulated ROS activates Apoptosis signal-regulating 
kinase 1 (ASK1) and leads to the subsequent activation of c-Jun N-terminal kinases 
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(represented by “JNK”)68. Meanwhile, ASK1 activation can be inhibited by P21 through 
direct binding68. JNKs can also be activated by extracellular signal-regulated kinase kinase 
kinase 1 (MEKK1), which is activated by various stimulus such as ceramide69, TGF receptors 
(TGFR)70 and TNF receptors (TNFR)12. JNKs promote intestinal carcinogenesis through their 
ability to phosphorylate c-jun and to activate AP171, 72. Studies have also shown that the 
activation of c-jun could be facilitated by ERK/MAPK pathway73 or -catenin/TCF4 
signaling71. An “AND” is then used between JNK and other activators since the initial 
phosphorylation of c-jun by JNKs is considered essential for the transcriptional activity of 
c-jun and AP130. The transcriptional activity of c-jun is inhibited through phosphorylation by 
glycogen synthase kinase-3 (represented as “GSK3B”). GSK3- plays a key role in regulating 
Wnt/-catenin signaling. GSK3- normally forms a complex with axin and adenomatous 
polyposis coli (represented by “APC”), which sequesters -catenin in the cytoplasm74. The 
phosphorylation of -catenin by GSK3- leads to its ubiquitination and subsequent 
degradation by cellular proteosomes, thus preventing the nuclear translocation of -catenin 
and the activation of its target gene, cyclin D1 (represented by “CYCLIND1”)75. Either 
inhibition of GSK3-, by PGE2 signaling29 or Akt/PKB pathway76, or inactive mutation of 
APC results in the increased activation of -catenin, which has been commonly observed in 
colon cancers77. Except for -catenin, the activation of STAT316 or c-jun78 transcription 
factors also leads to the up-regulation of cyclin D1, which is required for cell cycle 
progression and cell proliferation. Cyclin D1 has also been shown to be inhibited by GSK3- 
through direct phosphorylation79. The proliferation state can be inhibited by the activation of 
caspase-3 or P21, which can induce apoptosis and cell cycle arrest respectively. 
 
P53* = (PTEN or JNK or ATM) and not MDM2 
MDM2* = (P53 and AKT) and not (GSK3B or ATM) 
ATM* = ROS 
P21* = (P53 or SMAD) and not (GSK3B or CASP3) 
SMAD* = TGFR and not JUN 
TGFR* = TGFB and not SMAD7 
SMAD7* = SMAD or NFKB 
 
Mutations of the tumor suppressor gene TP53 and its product p53 (represented by “P53) have 
been widely observed in sporadic colon cancer as well as CAC. P53 and its down-stream 
target MDM2 form a negative feedback loop that keeps the level of p53 low in the absence of 
p53-stabilizing signals80. Although the MDM2 gene can be up-regulated by P53, the 
phosphorylation of MDM2 by Akt/PKB (AKT) is required for the nuclear translocation of 
MDM2 and its p53 inhibiting activity81, 82. Therefore, an “AND” is used between “AKT” and 
“P53”. The phosphorylation of MDM2 by ATM or GSK3- has been shown to attenuate 
MDM2 mediated P53 ubiquitination and degradation83, 84, 85. P53 can be phosphorylated and 
activated by Ataxia telangiectasia mutated (ATM), which senses DNA damage caused by 
oxidative stress or other factors86. Oxidative stresses, such as the increased level of ROS, also 
activates ATM directly87. Stress-induced phosphorylation of p53 by JNKs leads to the 
stabilization of p5388, which plays a key role in regulating the apoptosis of colon carcinoma 
cells89. In addition, PTEN has also been shown to associate with p53 directly and enhances its 
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transactivation in a phosphatase-independent manner90, 91. P21Waf1/Cip1 (represented by P21) is 
a p53 target gene and is necessary for p53 mediated cell cycle arrest92, 93. The phosphorylation 
of p21Waf1/Cip1 by GSK-3 promotes its degradation94, 95 and it can also be cleaved by 
executioner caspases, such as caspase-3 in various cell types, including colon carcinoma 
cells96, 97. In addition, TGF- signaling through receptor-regulated Smads (R-SMADs, 
represented by “SMAD”) also induces p21 Waf1/Cip1 expression and leads to the growth arrest of 
IECs98. TGF- mediated transcriptional activity of R-SMADs can be down-regulated by 
c-Jun99. The inhibitory Smads (I-SMADs), such as SMAD7, can be up-regulated by 
R-SMADs100. However, SMAD7 inhibits the TGF- mediated activation of R-SMADs and 
therefore forms another negative feedback loop in the CAC network100, 101. In addition, NF-B 
has also been shown to suppress the TGF-/Smad pathway by transcriptional activation of the 
inhibitory Smad7102. 
 
TH1* = (IL12 or IFNG) and not (IL10 or TGFB or IL4) 
IL12* = DC or MAC 
TH2* = IL4 and not (IFNG or TGFB) 
IL4* = DC or TH2 
IFNG* = TH1 or CTL 
CTL* = IFNG and not TGFB 
MAC* = (IFNG or CCL2) and not IL10 
TREG* = (IL10 or DC) and not IL6 
TGFB* = TREG 
IL10* = TREG or TH2 
CCL2* = NFKB 
DC* =  (CCL2 or TNFA) and not IL10 
 
Various immune cells, cytokines and chemokines take part in the different periods during the 
development of IBDs as well as CAC progress. As potent antigen-presenting cells, intestine 
dendritic cells (DCs, represented by “DC”) play key roles in inflammatory responses in IBDs2. 
Dendritic cells recruit different types of immune cells depending on the cytokine 
microenvironment. IL-12 (represented by “IL12”) secreted by DCs activates type 1 T helper 
cells (Th1 helper cells, represented by “TH1”) and initiates Th1 immune response, which 
promotes cell-mediated immunity103. Activated Th1 cells produce interferon- (IFN-, 
represented by “IFNG”), which activates macrophages (represented by “MAC”)3, 104. IFN- is 
also able to up-regulate macrophage IL-12 production, and this enhanced IL-12/IFN- loop is 
likely to be involved in the chronic inflammation within the intestine3. In addition, Th1 cells 
mediate the activation of CD8+ cytotoxic T lymphocytes (represented by “CTL”) through the 
production of IL-2 and IFN- (IL2 and IFNG are collapsed into “IFNG”)105. The activated 
CTLs can in turn act as another source of IFN-106. On the other hand, IL-4 (IL-4, represented 
as “IL4”) secreted by dendritic cells guides the maturation of type 2 T helper cells (Th2 cells , 
represented by “TH2”), which initiate humoral immunity106, 107. Th1 responses and Th2 
responses counteract each other: Th1 responses are inhibited by Th2 cytokines such as IL-4 
and IL-10, while Th2 responses are inhibited by Th1 cytokines such as IFN-6. DCs can also 
drive the differentiation of regulatory T cells (represented by “TREG”), which produce 
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immune suppressive cytokines, TGF- (represented by “TGFB”) and IL-10 (represented by 
“IL10”)7, 8. IL-10 can inhibit the pro-inflammatory functions of a broad array of immune cells, 
such as Th1 cells, macrophages and DCs8, 108, 109. TGF- secreted by Tregs inhibits both Th1 
and Th2 responses and it can also potently inhibit immune surveillance mediated by CD8+ 
cytotoxic T lymphocytes110, 111 . Excessive IL-6 has been shown to suppress differentiation of 
Treg cells from naïve T cells112. Myeloid-derived immune cells such as macrophages and DCs 
have been shown to be recruited and activated by chemokine (C-C motif) ligand 2 (CCL2), 
which can be produced by IECs upon NF-B activation during inflammatory responses10, 113, 
114. In addition to CCL2, TNF- present in the microenvironment also enhances DC survival 
and maturation115, 116.   
 
Immunoblot analysis 
Cells were harvested in PIRA lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.1% 
SDS and 1% sodium deoxycholate, with protease and phosphatase inhibitors). Protein 
concentrations were determined using a BCA assay (Thermoscientific). Proteins were subjected to 
SDS-PAGE, transferred to PVDF membranes (Immobilon-P, Millipore) and blocked for 1 h at 
room temperature with 5% milk in 1 x TBST. Membranes were incubated overnight with 
antibodies as indicated and exposed to secondary HRP-conjuncted anti-mouse or anti-rabbit 
antibodies at 1:2000 to 1:5,000, respectively, for 1 h at room temperature. The antigen-antibody 
reaction was visualised with an enhanced chemiluminescence assay (Thermoscientific) or Femto 
chemiluminescence assay (Thermoscientific). The results shown are representative of at least three 
independent experiments. 
Cell viability assays 
HT29 cells were seeded in 96-well plates at densities of 3103 cells per well. The following day, 
the cells were rinsed, and fresh medium was added with DMSO or the various indicated inhibitors 
for 48 h. Cell viability were assayed using sulforhodamine B (SRB). Briefly, the culture medium 
was aspirated, and RPMI 1640 medium with 10% trichloroacetic acid (TCA) was added to each 
well and allowed to stand for 24 h at 4°C to precipitate the proteins. Then, the precipitated 
proteins were stained for 15 min at room temperature with 0.4% (w/v) SRB in an acetic acid 
solution 1% v/v, washed with 1% acetic acid 5 times and then dried. The adherent SRB was 
solubilised in 10 mmol/l Tris buﬀer. Finally, the absorbance (optical density, OD) was read at a 
wavelength of 560 nm on an ELISA plate reader. Cell viability was measured as survival rate, 
which was calculated as follows: (OD treated/OD control) × 100%. 
siRNA  
siRNAs were ordered as RP-HPLC-purified duplexes from Sigma-Aldrich. The sequences were as 
follows:  
si-AKT1-#1: GUGCCAUGAUCUGUAUUUdTdT (sense);  
si-AKT1-#2: GAGACUGACACCAGGUAUUdTdT (sense); 
si-AKT2-#1: CUCUUCGAGCUCAUCCUCAdTdT (sense); 
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si-AKT2-#2: CAGAAUGCCAGCUGAUGAAdTdT (sense); 
si-AKT3-#1: GAAAGAUUGUGUACCGUGAdTdT (sense); and  
si-AKT3-#2: GACAUUAAAUUUCCUCGAAdTdT (sense). 
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